International Flavors & Fragrances (IFF)
Materials · Specialty Chemicals / Ingredients · NYSE
A global ingredient powerhouse providing the essential flavors, scents, and bioscience-based solutions that define the world's leading consumer brands.
What International Flavors & Fragrances does
International Flavors & Fragrances (IFF) is a global leader in the development and production of specialized ingredients and solutions for the food, beverage, health, biosciences, and scent markets. The company provides a broad portfolio of flavors, fragrances, enzymes, cultures, soy proteins, and probiotics used by manufacturers in consumer goods and industrial applications. IFF operates through a complex supply chain to integrate its science-based solutions into finished products across multiple categories.
Themes: food and beverage innovation, bioscience and health ingredients, consumer product scents, industrial biotechnology, portfolio restructuring
Fundamentals
- Price$84.28 as of 2026-08-21 close
- Market cap$21.5B as of 2026-08-21
- 1-year return+27.4% 2025-08-21 close $66.13 → 2026-08-21 close $84.28
- P/E74.04 as of 2026-08-24
- Net margin+2.9% as of 2026-08-24
- Gross margin+37.5% as of 2026-08-24
- ROE+2.1% as of 2026-08-24
- Debt / equity0.41 as of 2026-08-24
- Revenue growth (YoY)-11.7% as of 2026-08-24
- Revenue CAGR (3y)-4.3% SEC XBRL
- Beta0.93 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +4.3%; 2-year non-decreasing per-share dividend streak (SEC XBRL).
How IFF compares in its sector
- price-to-earnings ratiotop 25% 94 covered Materials peers, as of 2026-08-24
- net profit marginmiddle range 142 covered Materials peers, as of 2026-08-24
- operating marginmiddle range 142 covered Materials peers, as of 2026-08-24
- gross margintop 25% 141 covered Materials peers, as of 2026-08-24
- return on equitymiddle range 151 covered Materials peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 127 covered Materials peers
- indicated dividend yieldtop 25% 95 covered Materials peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 124 covered Materials peers, as of FY2025
Position among covered Materials companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IFF is not currently in any published Top 10 list. Its scores are below.
Long-term score
34.2 #913 of 987 scored · #55 of 66 in Materials
Long-term trend 73rd (it is 5.6% below its highest point of the past year) and financial health 44th (debt to equity 0.4, free cash flow margin 5.4%); weakest is growth (8th, revenue growth year over year -11.7%, 3-year revenue CAGR -4.3%).
Short-term score
56.5 #387 of 1,704 scored · #21 of 83 in Materials
Trend 65th: a trend forming but not yet strong (ADX below 25); catalysts 64th: the analyst consensus rating has improved toward "buy" since the prior reading; weakest is volume and participation 29th: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, IFF's dividend exceeded at least one reported measure of what it earned or generated (free-cash-flow payout 160%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payoutnot assessable earnings not reported
- Free-cash-flow payout160% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How International Flavors & Fragrances looks technically
International Flavors & Fragrances (IFF) is trading 14.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 128 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day high about 13 trading days ago.
Trend
7
| Distance from the 200-day | it is trading 14.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $79.37 | $79.37 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $73.33 | $73.33 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 128 trading days ago — a "golden cross", a bullish long-term signal | 128 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.9 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($79.47 to $89.31) — its "stochastic" reading is 49 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 48.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $89.31 | $89.31 |
|---|---|---|
| From the 52-week high | it is 5.6% below its 52-week high (its highest price of the past year) | -5.6% |
| Above the 52-week low | it is 42.5% above its 52-week low (its lowest price of the past year) | +42.5% |
| Below the 52-week high | it is 5.6% below its highest point of the past year | 5.6% |
| Since a 20-day breakout | it made a new 20-day high about 13 trading days ago | 13 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $157.40 (set on 2018-01-17) | $157.40 |
| Given back of the 52-week move | over the past year its closes ranged ($59.55 to $88.07), and it has given back only a small part of its rise from last year’s low — 13% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $69.53 to $70.44. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 13.3% |
| From the all-time high | it is 46.5% below its all-time high | -46.5% |
| Nearest price level | it is trading 0.8% above a support level at $83.57 — a price it turned at six times since 2025-02-10, most recently on 2026-07-02. Since 2024-08-21 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.8% |
| All-time low | its lowest closing price on record is $24.72 (set on 2008-11-20) | $24.72 |
| Above the all-time low | it is 240.9% above its all-time low | +240.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.39 between its high and its low — about 2.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.39 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $76.91 and $88.09 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $76.91 – $82.50 – $88.09 |
| Typical daily range (% of price) | its price moves about 2.8% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.8% |
| Stretch from the 200-day average | it is trading 4.6 daily ranges above its 200-day average price (14.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.70× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.05 toward buy |
Candlestick patterns
3
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.8% |
|---|---|---|
| Gap filled | a 2.9% gap down opened on 2026-07-23 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 19 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +4.05% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.2 percentage points (the stock gained 10.5% while the market gained 2.3%) | +8.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.9 percentage points (the stock gained 12.0% while the market gained 3.1%) | +8.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 7.5 percentage points (the stock gained 3.6% while the market gained 11.1%) | -7.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 7.0 percentage points (the stock gained 27.4% while the market gained 20.5%) | +7.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.2% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.7% of the share price. | +7.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 11% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $75.91 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +11.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $84.41 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | -0.2% |
Price levels it has turned at before
IFF last closed at $84.28 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $83.57 | Support | 0.8% below the last close | turned there six times · 2025-02-10 to 2026-07-02 |
| $87.30 | Resistance | 3.6% above the last close | turned there three times · 2024-11-06 to 2025-02-14 |
| $80.30 | Support | 4.7% below the last close | turned there five times · 2025-01-10 to 2026-07-17 |
| $78.53 | Support | 6.8% below the last close | turned there 7 times · 2025-02-20 to 2026-06-12 |
| $100.64 | Resistance | 19.4% above the last close | turned there three times · 2024-09-11 to 2024-10-07 |
| $106.01 | Resistance | 25.8% above the last close | turned there three times · 2024-09-03 to 2024-10-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bearish (12/26/9) · lagging the market · Trading above the Ichimoku cloud · Near a support level (sitting on a price it has bounced off before) | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$95.66 range $76.00 – $105.00; median $95.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IFF
- Consensus EPS estimate$0.7995 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant exposure to goodwill impairment and intangible asset valuation volatility.","Reliance on successful execution of portfolio restructuring and business divestitures.","Exposure to fluctuations in foreign currency exchange rates affecting global operations."]
What changed in the latest 10-Q
AI-assisted comparison of IFF's 10-Q filed 2026-05-05 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- New filing specifies company is organized into four reportable operating segments (newer filing removes Pharma Solutions from current segment count, though notes historical divestitures)
- Newer filing adds specific divestiture dates: SCL disposal group divested March 2, 2026; Rene Laurent divested December 1, 2025
- Newer filing includes detailed segment-level comparable currency neutral sales analysis table with three columns (Reported, Currency Neutral, Comparable Currency Neutral)
- Newer filing shows Q1 2026 results: net sales $2.741 billion, gross profit $1.018 billion (37.1% margin), operating profit $273 million
- Newer filing reports goodwill impairment of zero in Q1 2026 vs. $1.153 billion in Q1 2025
- Newer filing includes restructuring charges of $6 million in Q1 2026 vs. $17 million in Q1 2025
- Newer filing shows net income attributable to IFF shareholders of $169 million in Q1 2026 vs. loss of $(1,018) million in Q1 2025
- Newer filing reports EPS of $0.66 basic and diluted in Q1 2026 vs. $(3.98) in Q1 2025
- Removed:
- Older filing's opening statement references 2024 Form 10-K (filed February 28, 2025); newer filing references 2025 Form 10-K (filed February 27, 2026)
- Older filing describes company as 'a leading creator and manufacturer' with additional descriptive language about global leadership positions; newer filing uses simpler segment organization statement
- Older filing discusses Nourish segment reorganization effective January 1, 2025, creating Taste and Food Ingredients segments; newer filing presents these as established segments without reorganization detail
- Older filing includes Health & Biosciences description referencing 'documented clinical health claims' and 'industrial fermentation'; newer filing removes specific clinical health claims language
- Older filing discusses Cosmetic Ingredients business divestiture from Scent segment on April 2, 2024; newer filing does not mention this historical divestiture
- Older filing reports Q3 2025 results with net sales $2.694 billion, gross profit $983 million (36.5% margin); newer filing reports Q1 2026 different period results
- Older filing shows goodwill impairment of $1.153 billion in Q3 2024 comparison; newer filing shows zero impairment in Q1 2026
- Reworded:
- Food Ingredients segment description changed from 'natural and plant-based specialty food ingredients derived from herbs and plants' to 'natural, artificial and plant-based specialty food ingredients' (added 'artificial' descriptor)
- Food Ingredients segment changed from 'provide texturizing solutions used in the food industry' to 'provide functional properties solutions for food and beverage products' (broader functional language)
- Health & Biosciences segment description removed phrase 'this biotechnology-driven portfolio' and simplified clinical claims language in newer filing
- Scent segment description changed from 'we believe these make us a market leader' to removed market leadership claim language in newer filing
- Sales comparison context changed from Q3 2025 vs Q3 2024 (older filing) to Q1 2026 vs Q1 2025 (newer filing), reflecting different reporting periods
- Notes:
- The two filings compare different quarterly periods (Q1 2026 vs Q3 2025) and therefore financial metrics are not directly comparable for performance trend analysis
- Older filing is from Q3 2025 reporting period while newer filing is from Q1 2026 reporting period, representing sequential quarterly reports rather than same-period comparisons
- Divestitures occurred between the two filing dates (SCL, Rene Laurent, Pharma Solutions, Nitrocellulose) which materially affect segment composition and comparability
- Goodwill impairment of $1.153 billion in older filing's Q3 2024 comparison is not directly comparable to Q1 2026 results in newer filing
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($754970) — 1 selling insider
- Last 90 days2 buys ($20M) · 1 sell ($754970) — 1 buying, 1 selling insiders
- Last 180 days2 buys ($20M) · 1 sell ($754970) — 1 buying, 1 selling insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-06. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IFF's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for IFF from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding IFF as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 35,800,186
- Reported value $2,601,769,222
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IFF had 16,410,025 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IFF had 6.43% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.76 days to cover at the same settlement.
- Reported short interest (shares) 16,410,025
- Short interest (% of shares outstanding) 6.43%
- Prior settlement (shares) 15,027,612
- Reported change 9.2%
- Days to cover (reported) 9.76
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Givaudan
- Symrise AG
- Firmenich International SA
- Kerry Group (KRYAY)
- DSM-Firmenich (DSMFT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IFF vs…
International Flavors & Fragrances is found in…
Frequently asked questions
What does International Flavors & Fragrances (IFF) do?
International Flavors & Fragrances (IFF) is a global leader in the development and production of specialized ingredients and solutions for the food, beverage, health, biosciences, and scent markets. The company provides a broad portfolio of flavors, fragrances, enzymes, cultures, soy proteins, and probiotics used by manufacturers in consumer goods and industrial applications.
What sector is International Flavors & Fragrances (IFF) in?
International Flavors & Fragrances (IFF) is classified in the Materials sector. Its industry is Specialty Chemicals / Ingredients. It trades on NYSE.
Does IFF pay a dividend?
Yes — International Flavors & Fragrances (IFF) pays a dividend, with an indicated yield of about 4.34% and 2-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-08-24). Informational only — not financial advice.
Who are International Flavors & Fragrances's (IFF) competitors?
Notable peers of International Flavors & Fragrances (IFF) include Givaudan, Symrise AG, Firmenich International SA, Kerry Group and DSM-Firmenich. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in IFF?
Yes — we hold 3 matched STOCK Act disclosures for IFF from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is International Flavors & Fragrances (IFF) overbought or oversold right now?
International Flavors & Fragrances (IFF) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IFF come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.